Wall Street Insiders Are Loading Up on These 3 Stocks

"An "insider buy" is the legal purchase of a company's stock by its own executives, directors, or major shareholders. These buys are considered legal if they are properly disclosed to the Securities and Exchange Commission. The public can freely view these insider trades. Research shows that insider purchase patterns are often good signals for buying and selling, with stocks that have insider buying outperforming the overall market by 6% to 10.2% per year."

"Scholar Rock Holding (SRRK) is a clinical-stage biopharmaceutical company for diseases where protein growth factors play a central role. It does not yet have commercial products. It generates revenue primarily through collaboration and licensing agreements with larger pharmaceutical partners. The company's Director Srinivas Akkaraju made three buys of the stock in early October, all filed this Tuesday. His first buy was worth $14.44 million, followed by two more worth $697.71k and $3.67 million, respectively."

"This is a very strong vote of confidence, as previous insider trades have been planned and pre-announced sales from other officers and directors. The likely rationale comes from Phase 3 SAPPHIRE data showing apitegromab improved motor milestones in a statistically significant way. Approval is possible in both Europe and the U.S. next year . This could push the stock up even higher."

Insider buys are legal purchases of a company's stock by executives, directors, or major shareholders and are legal when properly disclosed to the SEC. The public can view insider trades. Research finds insider purchase patterns often signal buy and sell opportunities, with stocks featuring insider buying outperforming the overall market by 6% to 10.2% annually. Examining stocks with numerous insider buys can identify potential investment opportunities. Scholar Rock Holding (SRRK) is a clinical-stage biopharma focused on diseases involving protein growth factors and lacks commercial products. SRRK generates revenue mainly through collaborations and licensing with larger pharmaceutical partners. Director Srinivas Akkaraju made three early-October purchases totaling about $18.8 million, suggesting confidence tied to Phase 3 SAPPHIRE data for apitegromab and potential approval next year.

Read at 24/7 Wall St.